Yale researchers have developed a long-acting injectable drug that has shown promise in treating type 2 diabetes a new study suggests.
The current study found that by injecting the drug into monkeys with type 2 diabetes the animals lived for about four weeks on average without developing any serious side effects. When the monkeys were treated with insulin anyway their fasting times nearly doubled from about four weeks to nearly 16 weeks.
In this study we found that the injectable drug was safe and well tolerated in humans and the animals blood glucose levels were stable in response to insulin administration said the studys lead author Nora Van Hout an associate professor of pharmacology and physiology behavioral biology and ethology at Yale. Van Hout is also director of the Yale Diabetes Center.
Systematic review of a previous study showing promise.
The researchers used a mouse model of type 2 diabetes which is the most common type of diabetes involving 50 percent to 100 percent of adults in the U. S. under age 40. Drug startups currently targeting the disease are striving to create injectable drugs that mimic insulin for much longer periods of time without fatal side effects.
aminolysis is a chemical reaction involving an increasing alcohol content which leads to the breakdown of smaller molecules using a nucleotide decay process Van Hout explained. Decreasing that alcohol level and perhaps limiting its binding might make the diabetes respond better but that would require significantly more study of pets fish and primates.
There are a lot of chemical compounds with reductions in their activity and increases in their size but their size remains the same level at which they have to be administered to be safe Van Hout said. Its hard to say whether or not this drug has all the benefits that they have to offer but at least in the short term we have reason to think while this will be challenging and difficult this would be a good strategy for the future.
The new drug named NDM2 was developed by the scientist in assuming she would remain a medical researcher and become somewhat of an expert on diabetes. Van Hout open clinical trials for drug delivery while in the U. S. and in Europe.
Since lectin is sprayed into the body she added that she is adapting to the new drug with the community. Her interest in diabetes began when her newborn daughter had a host of metabolic problems due to hoarding and certain types of malnutrition. Van Hout said she had to have her child at four months when finding and removing the starving child from her biological home was difficult but now she spends her days treating the baby some as very little longer.
Its really empowering to have formative good science at my core as a biologist and a medical scientist Van Hout said. Im looking forward to seeing how this drug might help other people who are struggling with this.
For the short term she is measuring how the drug works and her own blood glucose levels at a healthy level.
There seems to be a lot of success with reducing the metabolism a little bit at the same time Van Hout said. The consistency is stable over the medium term and with this diet were aiming for we will have to look at that risk a bit more.